PMID- 34150441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2190-1678 (Print)
IS  - 2190-1686 (Electronic)
IS  - 2190-1678 (Linking)
VI  - 12
IP  - 3
DP  - 2021 Jul
TI  - Comparative effects of insulin glulisine and lispro on postprandial plasma 
      glucose and lipid profile in Japanese patients with type 2 diabetes mellitus.
PG  - 330-335
LID - 10.1007/s13340-020-00475-1 [doi]
AB  - OBJECTIVE: The control of postprandial plasma glucose (PPG) excursions is 
      critical in the prevention of diabetic complications. Controversy remains on the 
      differences in postprandial actions of insulin glulisine and lispro. The aim of 
      this study was to define the differences in the efficacy of these two insulin 
      analogues on PPG. METHODS: The study subjects were 20 in-hospital patients with 
      type 2 diabetes mellitus (T2DM). Plasma glucose (PG) was tightly controlled with 
      basal insulin and insulin glulisine or lispro, and then glulisine or lispro were 
      switched to the other insulin analog every other day for 6 study days. PG was 
      measured before breakfast and 0.5-, 1-, and 2 h-postprandial during the study. 
      Postprandial plasma C-peptide and lipids were analyzed in the first 2 days of the 
      study. Postprandial increments in each parameter were compared between glulisine 
      and lispro. RESULTS: Whereas the median value of 0.5 h-Delta-PPG was comparable in 
      glulisine and lispro, the 1 h-Delta-PPG was significantly lower with lispro than with 
      glulisine (41 vs 53 mg/dl, respectively, p = 0.03). Similarly, the 2 h-Delta-PPG with 
      lispro was 10 mg/dl lower than that with glulisine (35 vs 45 mg/dl, respectively, 
      p = 0.05). In parallel with PPG, Delta-C-peptide at 1- and 2 h-postprandial were 
      significantly lower with lispro than glulisine (0.50 vs 0.75 ng/ml, respectively, 
      and 0.55 vs 0.75 ng/ml, respectively). The increment in LDL-C and HDL-C was 
      significantly lower with lispro than with glulisine at 0.5 h-postprandial. 
      CONCLUSION: Insulin lispro seems superior to glulisine in the control of PPG in 
      Japanese patients with T2DM.
CI  - (c) The Japan Diabetes Society 2020.
FAU - Yamada, Mika
AU  - Yamada M
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Suzuki, Jinya
AU  - Suzuki J
AUID- ORCID: 0000-0002-5670-3528
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Nakaya, Takahiro
AU  - Nakaya T
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Ichikawa, Mai
AU  - Ichikawa M
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Yamamoto, Katsushi
AU  - Yamamoto K
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Imagawa, Michiko
AU  - Imagawa M
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Sato, Satsuki
AU  - Sato S
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Fujii, Miki
AU  - Fujii M
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Zenimaru, Yasuo
AU  - Zenimaru Y
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Konoshita, Tadashi
AU  - Konoshita T
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
FAU - Ishizuka, Tamotsu
AU  - Ishizuka T
AD  - Third Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Fukui, Fukui, 910-1193 Japan. GRID: grid.163577.1. ISNI: 0000 0001 0692 8246
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC8172737
OTO - NOTNLM
OT  - Apolipoproteins
OT  - C-peptide
OT  - Cardiovascular diseases
OT  - Insulin analogue
OT  - Postprandial hyperglycemia
COIS- Conflict of interestAuthors Mika Yamada, Jinya Suzuki, Takahiro Nakaya, Mai 
      Ichikawa, Katsushi Yamamoto, Michiko Imagawa, Satsuki Sato, Miki Fujii, Yasuo 
      Zenimaru, Tadashi Konoshita, and Tamotsu Ishizuka declare that they have no 
      conflict of interest.
EDAT- 2021/06/22 06:00
MHDA- 2021/06/22 06:01
PMCR- 2021/11/17
CRDT- 2021/06/21 05:57
PHST- 2020/08/05 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2021/06/21 05:57 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/06/22 06:01 [medline]
PHST- 2021/11/17 00:00 [pmc-release]
AID - 475 [pii]
AID - 10.1007/s13340-020-00475-1 [doi]
PST - epublish
SO  - Diabetol Int. 2020 Nov 17;12(3):330-335. doi: 10.1007/s13340-020-00475-1. 
      eCollection 2021 Jul.